Published in J Am Soc Nephrol on June 01, 2005
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet (2012) 4.75
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med (2013) 2.74
Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP). Arch Intern Med (2012) 2.74
Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med (2014) 2.02
Blood pressure and stroke risk among diabetic patients. J Clin Endocrinol Metab (2013) 1.79
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial. Hypertension (2011) 1.65
BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. J Am Soc Nephrol (2014) 1.42
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol (2007) 1.22
Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care (2013) 1.21
Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis (2011) 1.18
Blood pressure j-curve: current concepts. Curr Hypertens Rep (2012) 1.18
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med (2012) 1.12
Blood pressure levels and stroke: J-curve phenomenon? Curr Hypertens Rep (2013) 1.00
Longitudinal Patterns of Blood Pressure, Incident Cardiovascular Events, and All-Cause Mortality in Normotensive Diabetic People. Hypertension (2016) 0.98
Hypertension in chronic kidney disease: navigating the evidence. Int J Hypertens (2011) 0.95
Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Med (2011) 0.95
Cardiovascular disease in patients with chronic kidney disease. Vasc Health Risk Manag (2009) 0.92
Relationship between blood pressure and incident chronic kidney disease in hypertensive patients. Clin J Am Soc Nephrol (2011) 0.87
Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care (2011) 0.86
Blood pressure lowering in patients with diabetes--one level might not fit all. Nat Rev Cardiol (2010) 0.86
The effects of comorbidity on the benefits and harms of treatment for chronic disease: a systematic review. PLoS One (2014) 0.84
Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure). Nephrol Dial Transplant (2015) 0.84
Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. Indian J Nephrol (2011) 0.83
Does chronic kidney disease modify the association between body mass index and cardiovascular disease risk factors. J Nephrol (2012) 0.82
Hypertension and chronic kidney disease: controversies in pathogenesis and treatment. Minerva Urol Nefrol (2013) 0.81
Extreme Elevations in Blood Pressure and All-Cause Mortality in a Referred CKD Population: Results from the CRISIS Study. Int J Hypertens (2013) 0.80
Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. Clin J Am Soc Nephrol (2013) 0.80
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens (2011) 0.80
The impact of blood pressure on kidney function in the elderly: a cross-sectional study. Kidney Blood Press Res (2014) 0.79
Chapter 4: Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Suppl (2011) (2012) 0.79
Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT. J Am Soc Nephrol (2015) 0.79
Nephropathy in youth and young adults with type 2 diabetes. Curr Diab Rep (2014) 0.79
Effects of Intensive BP Control in CKD. J Am Soc Nephrol (2017) 0.78
Systolic blood pressure and outcomes in stage 3-4 chronic kidney disease patients: evidence from a Taiwanese cohort. Am J Hypertens (2014) 0.77
Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. J Investig Med (2010) 0.76
Impact of renal transplantation on cardiac morphological and functional characteristics in children and adults. World J Nephrol (2016) 0.75
Impact of baseline systolic blood pressure on visit-to-visit blood pressure variability: the Kailuan study. Ther Clin Risk Manag (2016) 0.75
The TRINITY Study: distribution of systolic blood pressure reductions. Integr Blood Press Control (2013) 0.75
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension (2016) 0.75
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences. J Clin Med (2015) 0.75
Coronary vasoregulation in health and disease. Can J Cardiol (2007) 0.75
Blood pressure and all-cause mortality among patients with type 2 diabetes. Int J Cardiol (2016) 0.75
The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease. Rambam Maimonides Med J (2015) 0.75
Chapter 8: Future directions and controversies. Kidney Int Suppl (2011) (2012) 0.75
[Blood pressure goals on the test bench]. Wien Klin Wochenschr (2011) 0.75
Relationship between low blood pressure and renal/cardiovascular outcomes in Japanese patients with chronic kidney disease under nephrologist care: the Gonryo study. Clin Exp Nephrol (2015) 0.75
Blood Pressure Before Initiation of Maintenance Dialysis and Subsequent Mortality. Am J Kidney Dis (2017) 0.75
Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ (2017) 0.75
[Hypertension and the kidney]. Wien Med Wochenschr (2008) 0.75
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med (2008) 11.61
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med (2004) 6.52
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis (2009) 4.30
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 4.27
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int (2003) 3.90
Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis (2010) 3.87
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med (2008) 3.71
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Controversies in ventricular remodelling. Lancet (2006) 3.39
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Heart failure. Lancet (2005) 3.33
Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J (2005) 3.09
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation (2007) 2.95
The burden of kidney disease: improving global outcomes. Kidney Int (2004) 2.94
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation (2005) 2.78
Dipstick pseudohematuria: unnecessary consultation and evaluation. J Urol (2009) 2.75
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation (2006) 2.68
Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol (2006) 2.68
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65
Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design. J Diabetes Complications (2005) 2.64
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation (2011) 2.62
Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation (2003) 2.62
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol (2006) 2.57
Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg (2005) 2.53
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med (2012) 2.51
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol (2004) 2.47
Effect of computerized clinical decision support on the use and yield of CT pulmonary angiography in the emergency department. Radiology (2011) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47